# Ototoxicity and Hearing Conservation

## Introduction

**Ototoxicity** refers to the damaging effect of certain medications and chemicals on the inner ear structures, resulting in hearing loss, tinnitus, and/or vestibular dysfunction. With the widespread use of ototoxic agents in clinical practice, the otolaryngologist must be familiar with the common offending drugs, monitoring protocols, and strategies for hearing conservation. Additionally, **noise-induced hearing loss (NIHL)** is a major preventable cause of sensorineural hearing loss.

## Anatomy of Ototoxic Injury

### Cochlear Toxicity
Primarily targets the **outer hair cells (OHCs)** of the organ of Corti. Damage begins at the **basal turn** (high frequencies) and progresses apically. Results in **high-frequency sensorineural hearing loss** initially. Severe toxicity involves inner hair cells and spiral ganglion neurons.

### Vestibular Toxicity
Targets **Type I hair cells** of the vestibular neuroepithelium. Affects the cristae of the semicircular canals and maculae of the utricle and saccule. Results in oscillopsia, disequilibrium, and bilateral vestibular hypofunction.

### Stria Vascularis Toxicity
Loop diuretics primarily affect the **stria vascularis**, disrupting the endocochlear potential. Usually reversible upon drug discontinuation.

## Common Ototoxic Medications

| Drug Class | Key Agents | Primary Toxicity | Reversibility |
|-----------|-----------|-----------------|---------------|
| Aminoglycosides | Gentamicin, amikacin, neomycin, streptomycin | Cochlear (amikacin, neomycin) or vestibular (gentamicin, streptomycin) | Irreversible |
| Platinum agents | Cisplatin, carboplatin | Cochlear (OHC, stria vascularis) | Irreversible; cumulative |
| Loop diuretics | Furosemide, ethacrynic acid | Stria vascularis | Usually reversible |
| Salicylates | Aspirin (high dose) | OHC (prestin inhibition) | Reversible |
| Macrolides | Erythromycin (high IV dose) | Cochlear | Reversible |

### Aminoglycoside Antibiotics
**Gentamicin, tobramycin, amikacin, streptomycin, neomycin**. Mechanism: generate reactive oxygen species (ROS) in hair cells; enter through mechanoelectric transduction channels. **Gentamicin**: preferentially vestibulotoxic. **Amikacin and neomycin**: preferentially cochleotoxic. **Streptomycin**: primarily vestibulotoxic (exploited therapeutically for Meniere disease). Risk factors: renal impairment, prolonged use, concurrent ototoxic drugs, genetic susceptibility (**MT-RNR1 mitochondrial mutation**). Damage is dose-dependent and often **irreversible**.

### Cisplatin and Carboplatin
**Cisplatin**: most ototoxic chemotherapeutic agent; affects the OHCs and stria vascularis. Bilateral, symmetric, high-frequency SNHL; dose-dependent and cumulative. Incidence: 50-80% of patients receiving cisplatin develop some hearing loss. **Carboplatin**: less ototoxic than cisplatin but still significant, especially in children. **Sodium thiosulfate**: FDA-approved otoprotectant for cisplatin-related ototoxicity in pediatric patients with localized, non-metastatic solid tumors.

### Loop Diuretics
**Furosemide, ethacrynic acid, bumetanide**. Mechanism: inhibit Na-K-2Cl cotransporter in the stria vascularis; reduce endocochlear potential. Usually **reversible** with dose reduction or discontinuation. Risk greatly increased with concurrent aminoglycoside use (synergistic ototoxicity).

### Salicylates and NSAIDs
**Aspirin** at high doses (4-8 g/day): tinnitus and bilateral SNHL. Mechanism: inhibits prestin in OHCs, reduces cochlear blood flow. **Reversible** upon dose reduction.

### Other Ototoxic Agents
**Quinine and chloroquine**: tinnitus, SNHL (usually reversible). **Vancomycin**: ototoxic at high serum levels, especially with concurrent aminoglycosides. **Erythromycin**: at high IV doses, reversible SNHL. **Vincristine and nitrogen mustard**: vestibulotoxic and cochleotoxic.

![Diagram illustrating the sites of ototoxic injury in the cochlea, including outer hair cells, stria vascularis, and spiral ganglion](/images/ototoxicity-sites-of-injury.jpg)

## Ototoxicity Monitoring

### Who to Monitor
All patients receiving cisplatin-based chemotherapy. Patients on aminoglycosides for more than 5-7 days (or any duration with renal impairment). Patients on high-dose loop diuretics, especially with concurrent ototoxic medications. Patients reporting new tinnitus or hearing change during ototoxic drug therapy.

### Monitoring Protocol (ASHA Guidelines)
**Baseline audiogram** before initiating ototoxic therapy (within 72 hours of first dose). **Serial audiometry** during treatment: frequency depends on agent and protocol. **Extended high-frequency audiometry** (9-20 kHz): earliest changes detected in ultra-high frequencies. **OAE (otoacoustic emissions)**: DPOAE monitoring detects early OHC dysfunction before audiometric changes. **Significant ototoxic change**: >=20 dB shift at any single frequency, >=10 dB shift at two consecutive frequencies, or loss of response at three consecutive frequencies where responses were previously obtained.

### Management of Detected Ototoxicity
Communicate findings to the oncologist/treating physician. Risk-benefit analysis: may modify dosing, switch agents, or accept hearing loss if life-saving treatment. Hearing rehabilitation: hearing aids, cochlear implant for severe bilateral loss. Vestibular rehabilitation for vestibulotoxicity.

## Noise-Induced Hearing Loss (NIHL)

### Pathophysiology
Excessive noise causes **mechanical shear stress** and **metabolic exhaustion** of hair cells. Temporary threshold shift (TTS): recoverable hearing loss after noise exposure. **Permanent threshold shift (PTS)**: irreversible loss from hair cell death. Noise exposure exceeding **85 dB for 8 hours** (OSHA action level) is hazardous. Every 3 dB increase halves the safe exposure time (exchange rate). Classic audiometric pattern: **4 kHz notch** (dip at 4000 Hz with recovery at 8000 Hz).

### Risk Factors
Occupational noise (construction, military, manufacturing, music industry). Recreational noise (firearms, concerts, personal listening devices). Combined exposure with ototoxic chemicals (solvents, heavy metals).

### Prevention and Hearing Conservation Programs
**Engineering controls**: reduce noise at the source. **Administrative controls**: limit exposure duration, rotate workers. **Personal hearing protection**: earplugs (NRR 15-30 dB), earmuffs (NRR 20-35 dB). **Annual audiometric monitoring** for noise-exposed workers (OSHA standard). **Education**: awareness of hazardous noise levels and proper HPD use.

![Audiogram showing the classic 4 kHz notch pattern of noise-induced hearing loss](/images/nihl-audiogram-4k-notch.jpg)

## Emerging Otoprotective Strategies

**N-acetylcysteine (NAC)**: antioxidant; some evidence for protection against noise and cisplatin. **D-methionine**: antioxidant; Phase III trials for cisplatin otoprotection. **Sodium thiosulfate**: FDA-approved for cisplatin ototoxicity in pediatric cancers. **Dexamethasone intratympanic injection**: may mitigate cisplatin ototoxicity. **Gene therapy and hair cell regeneration**: investigational; targeting Atoh1/Math1 for hair cell regeneration.

![Comparison of normal cochlear histology versus ototoxic damage showing outer hair cell loss in the basal turn](/images/ototoxic-hair-cell-damage.jpg)

## Key Clinical Pearls

Ototoxic hearing loss begins at **high frequencies** and is often not noticed by the patient until speech frequencies are affected. **Baseline audiometry** before initiating ototoxic therapy is essential and often omitted. Aminoglycoside ototoxicity is often **irreversible**; the MT-RNR1 mitochondrial mutation confers extreme susceptibility. **Cisplatin ototoxicity** is cumulative and dose-dependent; monitoring should continue even after treatment ends. The combination of **aminoglycosides and loop diuretics** is synergistically ototoxic and should be avoided when possible. The **4 kHz notch** on audiometry is the hallmark of noise-induced hearing loss and helps distinguish it from presbycusis.

## References

1. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. *Tohoku J Exp Med*. 2009;219(3):177-186.
2. Fausti SA, Henry JA, Helt WJ, et al. An individualized, sensitive frequency range for early detection of ototoxicity. *Ear Hear*. 1999;20(6):497-505.
3. Basner M, Babisch W, Davis A, et al. Auditory and non-auditory effects of noise on health. *Lancet*. 2014;383(9925):1325-1332.
4. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. *ASHA Guidelines*. 1994.